RATIONALE & OBJECTIVE: Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM). STUDY DESIGN: Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial. SETTING & PARTICIPANTS: Patients 18 years or older with hyperuricemia, albuminuria, and T2DM. INTERVENTION: Patients randomly assigned 1:1 to verinurad (9mg) plus febuxostat (80mg) or matched placebo once daily for 24 weeks. OUTCOMES: The primary end point was change in urinary albumin-creatinine ratio (UACR) from baseline after 12 weeks' treatment. Secondary end points included safety and tolerability and effect on glomerular filtration. RESULTS: 60 patients were enrolled (n=32, verinurad and febuxostat; n=28, placebo). UACRs after treatment with verinurad plus febuxostat were lower than after placebo at 1, 12, and 24 weeks: -38.6% (90% CI, -60.9% to-3.6%), -39.4% (90% CI, -61.8% to-3.8%), and-49.3% (90% CI, -68.2% to-19.0%), respectively. Serum urate levels after treatment with verinurad plus febuxostat were 59.6% and 63.7% lower than after placebo at 12 and 24 weeks, respectively. No clinically meaningful changes were observed in estimated glomerular filtration rate or serum creatinine or serum cystatin C concentrations. Verinurad plus febuxostat was well tolerated. LIMITATIONS: Sample size and study duration were insufficient to evaluate definitive effects of verinurad plus febuxostat on UACR and glomerular filtration. Generalizability was limited by exclusion of patients with stages 4 and 5 chronic kidney disease. CONCLUSIONS: Verinurad plus febuxostat reduced albuminuria and lowered serum urate concentrations in patients with T2DM, albuminuria, and hyperuricemia. Definitive assessment of their combined impact on preservation of kidney function awaits larger clinical studies. FUNDING: This study was supported by AstraZeneca. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03118739.
RATIONALE & OBJECTIVE: Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM). STUDY DESIGN: Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial. SETTING & PARTICIPANTS: Patients 18 years or older with hyperuricemia, albuminuria, and T2DM. INTERVENTION: Patients randomly assigned 1:1 to verinurad (9mg) plus febuxostat (80mg) or matched placebo once daily for 24 weeks. OUTCOMES: The primary end point was change in urinary albumin-creatinine ratio (UACR) from baseline after 12 weeks' treatment. Secondary end points included safety and tolerability and effect on glomerular filtration. RESULTS: 60 patients were enrolled (n=32, verinurad and febuxostat; n=28, placebo). UACRs after treatment with verinurad plus febuxostat were lower than after placebo at 1, 12, and 24 weeks: -38.6% (90% CI, -60.9% to-3.6%), -39.4% (90% CI, -61.8% to-3.8%), and-49.3% (90% CI, -68.2% to-19.0%), respectively. Serum urate levels after treatment with verinurad plus febuxostat were 59.6% and 63.7% lower than after placebo at 12 and 24 weeks, respectively. No clinically meaningful changes were observed in estimated glomerular filtration rate or serum creatinine or serum cystatin C concentrations. Verinurad plus febuxostat was well tolerated. LIMITATIONS: Sample size and study duration were insufficient to evaluate definitive effects of verinurad plus febuxostat on UACR and glomerular filtration. Generalizability was limited by exclusion of patients with stages 4 and 5 chronic kidney disease. CONCLUSIONS: Verinurad plus febuxostat reduced albuminuria and lowered serum urate concentrations in patients with T2DM, albuminuria, and hyperuricemia. Definitive assessment of their combined impact on preservation of kidney function awaits larger clinical studies. FUNDING: This study was supported by AstraZeneca. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT03118739.
Authors: Andrew S Levey; Ron T Gansevoort; Josef Coresh; Lesley A Inker; Hiddo L Heerspink; Morgan E Grams; Tom Greene; Hocine Tighiouart; Kunihiro Matsushita; Shoshana H Ballew; Yingying Sang; Edward Vonesh; Jian Ying; Tom Manley; Dick de Zeeuw; Kai-Uwe Eckardt; Adeera Levin; Vlado Perkovic; Luxia Zhang; Kerry Willis Journal: Am J Kidney Dis Date: 2019-08-28 Impact factor: 8.860
Authors: Carmen Mora-Fernández; Virginia Domínguez-Pimentel; Mercedes Muros de Fuentes; José L Górriz; Alberto Martínez-Castelao; Juan F Navarro-González Journal: J Physiol Date: 2014-06-06 Impact factor: 5.182
Authors: Stefan D Anker; Wolfram Doehner; Mathias Rauchhaus; Rakesh Sharma; Darrel Francis; Christoph Knosalla; Constantinos H Davos; Mariantonietta Cicoira; Waqar Shamim; Michel Kemp; Robert Segal; Karl Josef Osterziel; Francisco Leyva; Roland Hetzer; Piotr Ponikowski; Andrew J S Coats Journal: Circulation Date: 2003-04-21 Impact factor: 29.690
Authors: Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg Journal: N Engl J Med Date: 2008-06-05 Impact factor: 91.245
Authors: Yuka Sato; Daniel I Feig; Austin G Stack; Duk-Hee Kang; Miguel A Lanaspa; A Ahsan Ejaz; L Gabriela Sánchez-Lozada; Masanari Kuwabara; Claudio Borghi; Richard J Johnson Journal: Nat Rev Nephrol Date: 2019-07-11 Impact factor: 28.314
Authors: Susanne Johansson; David Han; Thomas Hunt; Karin Björck; Delia Florica; Michael Gillen; Jesse Hall; Fredrik Erlandsson Journal: Pharmacol Res Perspect Date: 2022-06
Authors: Danii L S Suijk; Michaël J B van Baar; Erik J M van Bommel; Zainab Iqbal; Merle M Krebber; Volker Vallon; Daan Touw; Ewout J Hoorn; Max Nieuwdorp; Mark M H Kramer; Jaap A Joles; Petter Bjornstad; Daniël H van Raalte Journal: Clin J Am Soc Nephrol Date: 2022-03-23 Impact factor: 10.614
Authors: Christopher Jenkins; Jennifer H Hwang; Jeffrey B Kopp; Cheryl A Winkler; Sung Kweon Cho Journal: Front Pharmacol Date: 2022-08-23 Impact factor: 5.988
Authors: Hiddo J L Heerspink; Austin G Stack; Robert Terkeltaub; Tom A Greene; Lesley A Inker; Magnus Bjursell; Shira Perl; Tord Rikte; Fredrik Erlandsson; Vlado Perkovic Journal: Nephrol Dial Transplant Date: 2022-07-26 Impact factor: 7.186